论文部分内容阅读
慢性HCV感染 BILN 2061 BILN 2061是一种有效而特异性的HCV丝氨酸蛋白酶抑制剂。Hinrichsen等对31例丙型肝炎基因1型及轻微肝纤维化的患者分别口服不同剂量的BILN 2061(25mg、200mg或500mg,2次/d),连续2天。每组患者随机以2:8的比例给予安慰剂。采用25mg、200mg和500mg BILN 2061进行治疗的3组患者中,分别有7/9、8/8和8/8的患者病毒载量下降了≥1Log_(10)单位,而安慰剂组的患者对治疗无反应。Benhamou等研究随机给予10例HCV基因1型和早期肝纤维化的患者BILN 2061(200mg,2次/d),或安慰剂治疗2天的效果。结果口服BILN 2061
Chronic HCV Infection BILN 2061 BILN 2061 is a potent and specific HCV serine protease inhibitor. Hinrichsen and other 31 patients with hepatitis C virus genotype 1 and mild liver fibrosis were given different doses of BILN 2061 (25mg, 200mg or 500mg, 2 times / d) for 2 consecutive days. Patients in each group were randomized to placebo at a 2: 8 ratio. Of the three groups treated with 25 mg, 200 mg, and 500 mg BILN 2061, there were 7/9, 8/8, and 8/8 patients, respectively, whose viral load decreased by> 1 Log 10 units, whereas patients in the placebo group No response to treatment. Benhamou et al. Studied the effects of BILN 2061 (200 mg twice daily) or placebo for 2 days in 10 patients with HCV genotype 1 and early liver fibrosis randomly. Results Oral BILN 2061